title: Successful treatment of disseminated granuloma annulare with adalimumab.
abstract: A 61-year-old female with a 4-year history of disseminated granuloma annulare was successfully treated with the antitumor necrosis factor (TNF)-alpha antibody, adalimumab. The patient had failed high potency topical glucocorticoids, hydroxychloroquine, and narrow-band ultraviolet light (UV)-B phototherapy. Anti-TNF-alpha therapy may be a therapeutic option in patients with disseminated granuloma annulare poorly controlled with conventional medications.
authors.affiliation: Tufts Medical Center, Tufts University School of Medicine, Department of Dermatology, Boston, MA, USA.
authors.forename: David
authors.initials: D
authors.lastname: Rosmarin
authors.forename: Anne
authors.initials: A
authors.lastname: LaRaia
authors.forename: Scott
authors.initials: S
authors.lastname: Schlauder
authors.forename: Alice B
authors.initials: AB
authors.lastname: Gottlieb
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001706:Biopsy; D005260:Female; D016460:Granuloma Annulare / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006644:Histiocytes / Q000473:pathology / Q000648:ultrastructure; D006801:Humans; D008875:Middle Aged; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab